STMN2 CA-repeat Biomarker for ALS Diagnosis and Prognosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for sporadic amyotrophic lateral sclerosis (ALS) lack effective pharmacological interventions due to limited understanding of the disease's pathogenesis and genetic basis, with few genetic markers explaining incidence, predisposition, progression, survival, and age of onset.
Innovation Solution
The presence of two long alleles of the STMN2 gene, with at least one allele comprising ≥ 24 consecutive CA dinucleotides, serves as a predictive marker for sporadic ALS, allowing for diagnosis, prognosis, and stratification of patients, enabling targeted treatments based on genetic predisposition and clinical indicators.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current standard treatments (symptomatic relief, riluzole, edaravone) are used for sporadic ALS, then patient survival and quality of life are modestly improved, but treatment effectiveness is limited due to lack of understanding of disease pathogenesis and genetic basis
Solution Approach 1:
The patent applies preliminary action by identifying and characterizing the STMN2 CA-repeat genetic marker before treatment decisions are made. Through genome-wide association studies and validation cohorts, the marker is established as a predictive indicator of disease risk, progression, and response to therapy, enabling clinicians to prepare personalized treatment strategies in advance rather than relying on trial-and-error approaches
Solution Approach 2:
The patent applies parameter changes by using the STMN2 CA-repeat genotype (number of cytosine-adenine repeats) as a stratification parameter to divide ALS patients into distinct risk groups. This genetic parameter enables differentiation between high-risk and low-risk patients, allowing treatment protocols to be adjusted based on individual genetic profiles rather than applying uniform standard care to all patients
2Measurement precision
If genome-wide association studies and validation cohorts are conducted to identify genetic markers, then predictive accuracy for age of onset, progression, and survival is improved, but diagnostic complexity and time required for marker identification increases
Solution Approach 1:
The patent applies taking out by extracting the specific STMN2 CA-repeat region from the entire genome for focused analysis. Instead of examining all genetic variants, the invention isolates and sequences only the relevant 10-base pair CA-repeat region within the STMN2 gene, dramatically simplifying the diagnostic process while maintaining high predictive accuracy for ALS risk and clinical outcomes
Solution Approach 2:
The patent applies copying by using PCR amplification to generate multiple copies of the STMN2 CA-repeat region from patient DNA samples. This allows sufficient material to be produced for accurate sequencing and analysis, enabling reliable genotype determination without requiring large amounts of starting material or complex sample processing
3Reliability
If edaravone treatment is administered to ALS patients, then functional decline is reduced in a small subset of patients, but treatment benefit is not achieved in the majority of patients due to lack of patient stratification
Solution Approach 1:
The patent applies local quality by assigning different treatment recommendations to different local subgroups of patients based on their STMN2 genotype. High-risk patients (those with specific CA-repeat lengths) receive different management strategies compared to low-risk patients, optimizing treatment allocation to those most likely to benefit while avoiding unnecessary treatment in patients unlikely to respond
Data Source
AI summary
The present disclosure relates generally to methods and protocols for the diagnosis, prognosis and stratification of patients with, or at risk of developing, sporadic amyotrophic lateral sclerosis (ALS). In particular, the methods and protocols of the present disclosure are based on determination of the presence and number of cytosine (C) adenine (A) dinucleotide repeats (CA dinucleotides) within the STMN2 gene.